BPC-157

Regulatory status

Not FDA-approved for any use. Named by the FDA among bulk substances that may present significant safety risks in compounding (Category 2).

What the evidence shows

Dozens of rodent studies report accelerated healing of tendon, ligament, muscle, and gut tissue. Human data is limited to small, mostly unpublished or non-replicated reports; no adequately powered randomized human trial has been published.

Human evidence

Sparse. No published, adequately powered randomized controlled trials.

Animal & preclinical evidence

Extensive rodent literature across tendon, ligament, gastric, and vascular injury models, largely from a single research group.

Proposed mechanism

Proposed mechanisms from animal models include upregulation of growth-factor signaling (VEGF, EGR-1), promotion of angiogenesis, and modulation of the nitric-oxide system. Human mechanistic confirmation is lacking.

Potential risks

• Unknown human safety profile — no systematic human safety data exists
• Angiogenesis-promoting signaling raises theoretical concerns in undiagnosed malignancy
• Unregulated products carry dosing, purity, and contamination risk
• Injection-site reactions and infection risk with non-sterile technique

Contraindications

• Active or suspected cancer (theoretical angiogenesis concern)
• Pregnancy and breastfeeding — zero safety data
• Anyone without a prescribing clinician overseeing use

Common research endpoints

• Tendon-to-bone healing rate (rodent)
• Gastric lesion healing (rodent)
• Vascular recruitment / angiogenesis markers
• Functional recovery scores in injury models